CA088-1005
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 111 patients (estimated)
- Sponsors
- Juno Therapeutics, a Subsidiary of Celgene
- Tags
- CAR T Cell, Cereblon E3 Ligase Modulators (CELMoDs), CD3, GPRC5D
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1795
- NCT Identifier
- NCT06121843
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.